Neurocrine Bioscienc (NBIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2010 | 12-2009 | 12-2008 | 12-2007 | 12-2006 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -7,968 | -51,038 | -88,613 | -207,299 | -107,205 |
| Depreciation Amortization | 2,269 | 3,179 | 7,610 | 9,404 | 10,566 |
| Accounts receivable | -4,278 | 2,449 | 2,428 | 7,769 | -4,812 |
| Other Working Capital | -8,485 | -12,380 | -12,372 | 17,691 | -11,078 |
| Other Operating Activity | 68,405 | 4,695 | 16,782 | 113,101 | 13,195 |
| Operating Cash Flow | $49,943 | $-53,095 | $-74,165 | $-59,334 | $-99,334 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -54,948 | 10,815 | 45,146 | 22,492 | 122,866 |
| PPE Investments | 21 | 1,158 | -727 | -495 | -3,110 |
| Other Investing Activity | 223 | 84 | 1 | -1,161 | 525 |
| Investing Cash Flow | $-54,704 | $12,057 | $44,420 | $20,836 | $120,281 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | 108,745 | N/A |
| Debt Repayment | N/A | N/A | -1,486 | -52,155 | -5,763 |
| Common Stock Issued | 21,483 | 9,900 | 34 | 591 | 15,849 |
| Financing Cash Flow | $21,483 | $9,900 | $-1,452 | $57,181 | $10,086 |
| Beginning Cash Position | 37,329 | 68,467 | 99,664 | 80,981 | 49,948 |
| End Cash Position | 54,051 | 37,329 | 68,467 | 99,664 | 80,981 |
| Net Cash Flow | $16,722 | $-31,138 | $-31,197 | $18,683 | $31,033 |
| Free Cash Flow | |||||
| Operating Cash Flow | 49,943 | -53,095 | -74,165 | -59,334 | -99,334 |
| Capital Expenditure | -315 | -35 | -1,322 | -624 | -3,110 |
| Free Cash Flow | 49,628 | -53,130 | -75,487 | -59,958 | -102,444 |